These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26992239)

  • 1. MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.
    Soldevilla MM; Villanueva H; Casares N; Lasarte JJ; Bendandi M; Inoges S; López-Díaz de Cerio A; Pastor F
    Oncotarget; 2016 Apr; 7(17):23182-96. PubMed ID: 26992239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma.
    Strome SE; Martin B; Flies D; Tamada K; Chapoval AI; Sargent DJ; Shu S; Chen L
    J Immunother; 2000; 23(4):430-7. PubMed ID: 10916752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
    Schrand B; Berezhnoy A; Brenneman R; Williams A; Levay A; Kong LY; Rao G; Zhou S; Heimberger AB; Gilboa E
    Cancer Immunol Res; 2014 Sep; 2(9):867-77. PubMed ID: 24938283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
    Zhao X; Yuan C; Wangmo D; Subramanian S
    Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
    Pastor F; Kolonias D; McNamara JO; Gilboa E
    Mol Ther; 2011 Oct; 19(10):1878-86. PubMed ID: 21829171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
    Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
    J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for
    Zhang L; Zhou L; Zhang H; Zhang Y; Li L; Xie T; Chen Y; Li X; Ling N; Dai J; Sun X; Liu J; Zhao J; Peng T; Ye M
    ACS Appl Mater Interfaces; 2021 Nov; 13(46):54656-54664. PubMed ID: 34779207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
    Soldevilla MM; Villanueva H; Meraviglia-Crivelli D; Menon AP; Ruiz M; Cebollero J; Villalba M; Moreno B; Lozano T; Llopiz D; Pejenaute Á; Sarobe P; Pastor F
    Mol Ther; 2019 Nov; 27(11):1878-1891. PubMed ID: 31405808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD28 aptamers as powerful immune response modulators.
    Pastor F; Soldevilla MM; Villanueva H; Kolonias D; Inoges S; de Cerio AL; Kandzia R; Klimyuk V; Gleba Y; Gilboa E; Bendandi M
    Mol Ther Nucleic Acids; 2013 Jun; 2(6):e98. PubMed ID: 23756353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
    Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
    Pratico ED; Sullenger BA; Nair SK
    Nucleic Acid Ther; 2013 Feb; 23(1):35-43. PubMed ID: 23113766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.
    Diehl L; van Mierlo GJ; den Boer AT; van der Voort E; Fransen M; van Bostelen L; Krimpenfort P; Melief CJ; Mittler R; Toes RE; Offringa R
    J Immunol; 2002 Apr; 168(8):3755-62. PubMed ID: 11937526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.
    Conejo-Garcia JR; Benencia F; Courreges MC; Gimotty PA; Khang E; Buckanovich RJ; Frauwirth KA; Zhang L; Katsaros D; Thompson CB; Levine B; Coukos G
    Cancer Res; 2004 Mar; 64(6):2175-82. PubMed ID: 15026360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.